COVIVIO (COV.PA) Stock Fundamental Analysis

EPA:COV • FR0000064578

62.15 EUR
+0.8 (+1.3%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to COV. COV was compared to 42 industry peers in the Diversified REITs industry. COV has a medium profitability rating, but doesn't score so well on its financial health evaluation. COV has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year COV was profitable.
  • COV had a positive operating cash flow in the past year.
  • COV had positive earnings in 4 of the past 5 years.
  • Of the past 5 years COV 4 years had a positive operating cash flow.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B -1B

1.2 Ratios

  • COV has a Return On Assets (1.63%) which is comparable to the rest of the industry.
  • COV has a Return On Equity (5.08%) which is comparable to the rest of the industry.
  • Looking at the Return On Invested Capital, with a value of 3.21%, COV is in line with its industry, outperforming 47.62% of the companies in the same industry.
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROIC 3.21%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • COV's Profit Margin of 30.46% is in line compared to the rest of the industry. COV outperforms 47.62% of its industry peers.
  • COV's Profit Margin has improved in the last couple of years.
  • COV has a Operating Margin of 57.81%. This is in the lower half of the industry: COV underperforms 61.90% of its industry peers.
  • COV's Operating Margin has improved in the last couple of years.
  • COV has a Gross Margin (74.42%) which is in line with its industry peers.
  • COV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
OM growth 3Y11.41%
OM growth 5Y7.53%
PM growth 3Y16.3%
PM growth 5Y17.87%
GM growth 3Y2.18%
GM growth 5Y0.71%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for COV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • Based on the Altman-Z score of 0.56, we must say that COV is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 0.56, COV is not doing good in the industry: 69.05% of the companies in the same industry are doing better.
  • COV has a debt to FCF ratio of 28.49. This is a negative value and a sign of low solvency as COV would need 28.49 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 28.49, COV is doing worse than 66.67% of the companies in the same industry.
  • COV has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
  • COV has a Debt to Equity ratio of 1.07. This is in the lower half of the industry: COV underperforms 76.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Altman-Z 0.56
ROIC/WACC0.54
WACC5.92%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • COV has a Current Ratio of 0.76. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • COV has a better Current ratio (0.76) than 64.29% of its industry peers.
  • COV has a Quick Ratio of 0.76. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • COV has a better Quick ratio (0.69) than 64.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.69
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • COV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.26%.
  • Measured over the past 5 years, COV shows a small growth in Earnings Per Share. The EPS has been growing by 2.44% on average per year.
  • COV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.71%.
  • COV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.03% yearly.
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
Revenue 1Y (TTM)-11.71%
Revenue growth 3Y-8.88%
Revenue growth 5Y-2.03%
Sales Q2Q%40.47%

3.2 Future

  • Based on estimates for the next years, COV will show a small growth in Earnings Per Share. The EPS will grow by 2.19% on average per year.
  • COV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.15% yearly.
EPS Next Y0.64%
EPS Next 2Y2.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.51%
Revenue Next 2Y5.15%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 13.08, COV is valued correctly.
  • Based on the Price/Earnings ratio, COV is valued a bit cheaper than 69.05% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of COV to the average of the S&P500 Index (27.10), we can say COV is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 13.00, COV is valued correctly.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of COV is on the same level as its industry peers.
  • COV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 13.08
Fwd PE 13
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 61.90% of the companies in the same industry are more expensive than COV, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, COV is valued a bit more expensive than the industry average as 61.90% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 17.67
EV/EBITDA 17.76
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)20.49
PEG (5Y)5.36
EPS Next 2Y2.19%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 6.11%, COV is a good candidate for dividend investing.
  • COV's Dividend Yield is a higher than the industry average which is at 5.22.
  • COV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.83.
Industry RankSector Rank
Dividend Yield 6.11%

5.2 History

  • The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years2
Div Non Decr Years2
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • COV pays out 92.76% of its income as dividend. This is not a sustainable payout ratio.
DP92.76%
EPS Next 2Y2.19%
EPS Next 3YN/A
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

COVIVIO

EPA:COV (2/27/2026, 7:00:00 PM)

62.15

+0.8 (+1.3%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-18
Earnings (Next)07-20
Inst Owners42.11%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap6.94B
Revenue(TTM)1.15B
Net Income(TTM)417.86M
Analysts75
Price Target64.28 (3.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.11%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP92.76%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.66%
PT rev (3m)-0.22%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)2.79%
Valuation
Industry RankSector Rank
PE 13.08
Fwd PE 13
P/S 5.06
P/FCF 17.67
P/OCF 6.91
P/B 0.84
P/tB 0.88
EV/EBITDA 17.76
EPS(TTM)4.75
EY7.64%
EPS(NY)4.78
Fwd EY7.69%
FCF(TTM)3.52
FCFY5.66%
OCF(TTM)8.99
OCFY14.46%
SpS12.29
BVpS73.66
TBVpS70.57
PEG (NY)20.49
PEG (5Y)5.36
Graham Number88.73
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROCE 3.59%
ROIC 3.21%
ROICexc 3.42%
ROICexgc 3.48%
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
FCFM 28.62%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y11.41%
OM growth 5Y7.53%
PM growth 3Y16.3%
PM growth 5Y17.87%
GM growth 3Y2.18%
GM growth 5Y0.71%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Debt/EBITDA 9.39
Cap/Depr 415.79%
Cap/Sales 44.53%
Interest Coverage 250
Cash Conversion 106.76%
Profit Quality 93.95%
Current Ratio 0.76
Quick Ratio 0.69
Altman-Z 0.56
F-Score7
WACC5.92%
ROIC/WACC0.54
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
EPS Next Y0.64%
EPS Next 2Y2.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.71%
Revenue growth 3Y-8.88%
Revenue growth 5Y-2.03%
Sales Q2Q%40.47%
Revenue Next Year4.51%
Revenue Next 2Y5.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.73%
EBIT growth 3Y1.52%
EBIT growth 5Y5.34%
EBIT Next Year7.68%
EBIT Next 3Y7.22%
EBIT Next 5YN/A
FCF growth 1Y-30.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.27%
OCF growth 3YN/A
OCF growth 5YN/A

COVIVIO / COV.PA FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 3 / 10 to COV.PA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 3 / 10 to COVIVIO (COV.PA). This can be considered as Overvalued.


Can you provide the profitability details for COVIVIO?

COVIVIO (COV.PA) has a profitability rating of 4 / 10.


What is the financial health of COVIVIO (COV.PA) stock?

The financial health rating of COVIVIO (COV.PA) is 1 / 10.


How sustainable is the dividend of COVIVIO (COV.PA) stock?

The dividend rating of COVIVIO (COV.PA) is 4 / 10 and the dividend payout ratio is 92.76%.